AbbVie Touts Qulipta Chronic Migraine Win as Biohaven Duel Heats Up
Oral CGRP inhibitors made by AbbVie and Biohaven Pharmaceuticals are quickly gaining share in the migraine market. But unlike their injectable peers, the two oral options have their prevention labels limited to episodic patients. That might change soon….
Argenx’s Vyvgart launch finds quick neurologist support over AstraZeneca’s well-entrenched Soliris for myasthenia gravis
Argenx nabbed an FDA approval for its rare disease drug Vyvgart just before Christmas and is wasting no time launching the generalized myasthenia gravis (gMG) med and setting it up to compete with AstraZeneca’s Soliris.
AbbVie runs first Qulipta TV ad spots as it focuses on what you ‘can control inside’
AbbVie is going heavy on repetition with the first series of ads for its new preventative migraine drug, Qulipta. The drug, an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant), was FDA-approved late last year to prevent episodic migraine and launched around three months ago. AbbVie, a major TV ad spender, has wasted no time getting […]
Argenx’s Vyvgart Offers a Substantial Advance Over Other Treatments for Generalized Myasthenia Gravis, Spherix Survey Suggests
Physician-reported treatment patterns suggest that Vyvgart prescriber base and share could soon be competitive with those of Alexion’s (now AstraZeneca’s) Solaris EXTON, Pa., February 14, 2022 / PRNewswire/ — At the end of last year, argenx’s Vyvgart (efgartigimod alfa-fcab) was approved by the FDA for the treatment of generalized myasthenia gravis (gMG) in adult patients […]
AbbVie’s Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven’s Nurtec
AbbVie may have been second to the preventative migraine market after Biohaven’s Nurtec ODT, but the Big Pharma is getting prescribers onside. That’s according to a new report and analysis from Spherix, which found that Qulipta—approved last September—is already racing to catch up with Nurtec, which gained its second approval in May 2021 as a preventive […]
Robust Uptake of AbbVie’s Qulipta Turns Up the Pressure for Amgen, Eli Lilly, and Teva in the Prevention Segment of the Migraine Market, Spherix Reports
Needle aversion and oral therapy preference is costing new prescription opportunities for Amgen’s Aimovig, Eli Lilly’s Emgality, and Teva’s Ajovy EXTON, Pa., February 8, 2022 / PRNewswire/ — The September 2021 approval of Qulipta for the preventive treatment of episodic migraine has added a third asset to AbbVie’s (formerly Allergan’s) migraine portfolio. While most of […]
Neurologists pass on Aduhelm again. Most agree with CMS decision to limit coverage, study finds
A majority of neurologists agree with Medicare on the need for more data on Biogen and Eisai’s Alzheimer’s disease med Aduhelm, despite FDA approval. More than half (52%) of neurologists agree with the Centers for Medicare and Medicaid Services (CMS)…
CMS’ Biogen decision could spell problems for Lilly, Roche Alzheimer’s drugs, half of surveyed neurologists say
Neurologists in the U.S. are agreeing with a new draft decision from the Centers for Medicare & Medicaid Services (CMS) that restricts reimbursement of Biogen’s controversial Alzheimer’s disease drug, Aduhelm, to Medicare patients enrolled in approved clinical trials only. In fact, half of those surveyed said CMS’ decision would hit how they prescribe the rival […]
Neurologists React to CMS’ Proposed NCD Decision on Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease in the Latest from Spherix Global Insights
Insights capture the potential impact of the proposed NCD decision on Biogen/Eisai’s Aduhelm, Eli Lilly’s donanemab, Eisai/Biogen’s lecanemab, and Roche/Genentech’s gantenerumab EXTON, Pa., January 27, 2022 / PRNewswire/ — On January 11th, the Centers for Medicare and Medicaid Services (CMS)’ proposed Medicare reimbursement of FDA-approved anti-amyloid monoclonal antibodies (mAbs) be limited to clinical trials under […]
Efficacy Expectations for Refractory Migraine Patients are Vital for Strong Uptake of Impel’s Trudhesa, Spherix Reports
New research suggests Trudhesa is more likely to compete with Biohaven’s Nurtec ODT, AbbVie’s Ubrelvy, and Eli Lilly’s Reyvow over dihydroergotamine mesylate formulations for new prescriptions EXTON, Pa., January 13, 2022 / PRNewswire/ — Impel’s new entrant into the acute migraine landscape, the dihydroergotamine mesylate (DHE) nasal spray, Trudhesa, is off to a somewhat light […]
